Cerevance Parkinson’s drug shortens ‘off time’ in Ph. 3, paving path to FDA
Cerevance's Parkinson's disease drug shortened 'off time' in a Phase 3 trial, paving a path toward FDA review.
Cerevance
Biopharmaceutical company
Company Info
Recent News
Revance and Teoxane Announce the FDA Approval of RHA Redensity® Eye for Undereye Hollowing
Revance and Teoxane Announce the FDA Approval of RHA Redensity® Eye for Undereye Hollowing